Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, leading to the development of monoclonal antibo...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b46fe1fae9344ce2b6b50d9f95f3903c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b46fe1fae9344ce2b6b50d9f95f3903c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b46fe1fae9344ce2b6b50d9f95f3903c2021-11-25T18:07:06ZAssociation of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas10.3390/jpm111110952075-4426https://doaj.org/article/b46fe1fae9344ce2b6b50d9f95f3903c2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1095https://doaj.org/toc/2075-4426The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, leading to the development of monoclonal antibodies against this protein. CLDN18.2 is the dominant isoform of CLDN18 in normal gastric and gastric cancer tissues. In this work, we evaluated the immunohistochemical (IHC) profile of CLDN18 and its correlation with clinical and histopathological features including p53, E-cadherin, MSH2, MSH6, MLH1, PMS2, HER2, EBER and PD-L1 combined positive score, in a large real-world and mono-institutional series of advanced GCs (<i>n</i> = 280) and GECs (<i>n</i> = 70). The association of IHC results with survival outcomes was also investigated. High membranous CLDN18 expression (2+ and 3+ intensity ≥75%) was found in 117/350 (33.4%) samples analyzed. CLDN18 expression correlated with age <70 (<i>p</i> = 0.0035), positive EBV status (<i>p</i> = 0.002), high stage (III, IV) at diagnosis (<i>p</i> = 0.003), peritoneal involvement (<i>p</i> < 0.001) and lower incidence of liver metastases (<i>p</i> = 0.013). CLDN18 did not correlate with overall survival. The predictive value of response of CLDN18 to targeted agents is under investigation in several clinical trials and further studies will be needed to select patients who could benefit from these therapies.Antonio PellinoStefano BrignolaErika RielloMonia NieroSabina MurgioniMaria GuidoFloriana NappoGianluca BusinelloMarta SbaragliaFrancesca BergamoGaya SpolveratoSalvatore PucciarelliStefano MeriglianoPierluigi PilatiFrancesco CavallinStefano RealdonFabio FarinatiAngelo Paolo Dei TosVittorina ZagonelSara LonardiFotios LoupakisMatteo FassanMDPI AGarticleCLDN18.2gastric adenocarcinomabiomarkersimmunohistochemistryMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1095, p 1095 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
CLDN18.2 gastric adenocarcinoma biomarkers immunohistochemistry Medicine R |
| spellingShingle |
CLDN18.2 gastric adenocarcinoma biomarkers immunohistochemistry Medicine R Antonio Pellino Stefano Brignola Erika Riello Monia Niero Sabina Murgioni Maria Guido Floriana Nappo Gianluca Businello Marta Sbaraglia Francesca Bergamo Gaya Spolverato Salvatore Pucciarelli Stefano Merigliano Pierluigi Pilati Francesco Cavallin Stefano Realdon Fabio Farinati Angelo Paolo Dei Tos Vittorina Zagonel Sara Lonardi Fotios Loupakis Matteo Fassan Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| description |
The tight junction protein claudin-18 (CLDN18), is often expressed in various cancer types including gastric (GC) and gastroesophageal adenocarcinomas (GECs). In the last years, the isoform CLDN18.2 emerged as a potential drug target in metastatic GCs, leading to the development of monoclonal antibodies against this protein. CLDN18.2 is the dominant isoform of CLDN18 in normal gastric and gastric cancer tissues. In this work, we evaluated the immunohistochemical (IHC) profile of CLDN18 and its correlation with clinical and histopathological features including p53, E-cadherin, MSH2, MSH6, MLH1, PMS2, HER2, EBER and PD-L1 combined positive score, in a large real-world and mono-institutional series of advanced GCs (<i>n</i> = 280) and GECs (<i>n</i> = 70). The association of IHC results with survival outcomes was also investigated. High membranous CLDN18 expression (2+ and 3+ intensity ≥75%) was found in 117/350 (33.4%) samples analyzed. CLDN18 expression correlated with age <70 (<i>p</i> = 0.0035), positive EBV status (<i>p</i> = 0.002), high stage (III, IV) at diagnosis (<i>p</i> = 0.003), peritoneal involvement (<i>p</i> < 0.001) and lower incidence of liver metastases (<i>p</i> = 0.013). CLDN18 did not correlate with overall survival. The predictive value of response of CLDN18 to targeted agents is under investigation in several clinical trials and further studies will be needed to select patients who could benefit from these therapies. |
| format |
article |
| author |
Antonio Pellino Stefano Brignola Erika Riello Monia Niero Sabina Murgioni Maria Guido Floriana Nappo Gianluca Businello Marta Sbaraglia Francesca Bergamo Gaya Spolverato Salvatore Pucciarelli Stefano Merigliano Pierluigi Pilati Francesco Cavallin Stefano Realdon Fabio Farinati Angelo Paolo Dei Tos Vittorina Zagonel Sara Lonardi Fotios Loupakis Matteo Fassan |
| author_facet |
Antonio Pellino Stefano Brignola Erika Riello Monia Niero Sabina Murgioni Maria Guido Floriana Nappo Gianluca Businello Marta Sbaraglia Francesca Bergamo Gaya Spolverato Salvatore Pucciarelli Stefano Merigliano Pierluigi Pilati Francesco Cavallin Stefano Realdon Fabio Farinati Angelo Paolo Dei Tos Vittorina Zagonel Sara Lonardi Fotios Loupakis Matteo Fassan |
| author_sort |
Antonio Pellino |
| title |
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| title_short |
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| title_full |
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| title_fullStr |
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| title_full_unstemmed |
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas |
| title_sort |
association of cldn18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/b46fe1fae9344ce2b6b50d9f95f3903c |
| work_keys_str_mv |
AT antoniopellino associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT stefanobrignola associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT erikariello associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT monianiero associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT sabinamurgioni associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT mariaguido associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT floriananappo associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT gianlucabusinello associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT martasbaraglia associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT francescabergamo associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT gayaspolverato associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT salvatorepucciarelli associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT stefanomerigliano associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT pierluigipilati associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT francescocavallin associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT stefanorealdon associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT fabiofarinati associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT angelopaolodeitos associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT vittorinazagonel associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT saralonardi associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT fotiosloupakis associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas AT matteofassan associationofcldn18proteinexpressionwithclinicopathologicalfeaturesandprognosisinadvancedgastricandgastroesophagealjunctionadenocarcinomas |
| _version_ |
1718411637337096192 |